NEW YORK, April 07, 2016 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a shareholder class action lawsuit has been filed in in the United States District Court for the Southern District of Florida against Platform Specialty Products Corporation (“Platform Specialty” or the “Company”) (NYSE:PAH), representing investors who purchased or otherwise acquired shares between February 17, 2015 and March 14, 2016, inclusive (the “Class Period”).
Shareholders who have incurred losses in Platform Specialty Products Corporation securities are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.
If you purchased shares of Platform Specialty Products Corporation, you may, no later than May 31, 2016, request that the Court appoint you lead plaintiff of the proposed class.
According to the filed Complaint, on March 11, 2016, Platform Specialty disclosed in its 2015 annual report that the Company had “discovered certain payments made to third-party agents in connection with Arysta LifeScience Limited’s (“Arysta”) government tender business in West Africa which may be illegal or otherwise inappropriate” and had “engaged outside counsel and an outside accounting firm to conduct an internal investigation to review the legality of these and other payments . . . including Arysta’s compliance with the FCPA.”
Subsequently, on March 14, 2016, the Wall Street Journal published a story addressing the disclosures by Platform Specialty in its 2015 annual report, entitled Chemical Company Notifies U.S. of West Africa FCPA Probe.” On this news, shares of Platform Specialty fell over 7%, closing at $7.95 per share on March 15, 2016.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com. All e-mail correspondence should make reference to the “Platform Specialty investigation.”
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Washington Post Publisher Will Lewis Steps Down After Layoffs
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Anta Sports Expands Global Footprint With Strategic Puma Stake
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



